Literature DB >> 9614382

Hyaluronate binding assay study of transfected CD44 V4-V7 isoforms into the human gastric carcinoma cell line SC-M1.

H J Harn1, K L Shen, C A Liu, L I Ho, L S Yang, K C Yueh.   

Abstract

The potential human metastasis molecule CD44 and its isoforms V5 and V6 are overexpressed in human gastric carcinoma. Among the numerous extracellular matrix components, hyaluronate, a CD44 ligand, is of increasing interest in relation to its role in cancer cell development and invasion. By using the dynabead separation method, the SC-M1 cell line was separated into V5 and V6 isoform-positive and -negative populations. The V5 and V6 isoform-negative populations exhibited significantly higher hyaluronate binding activity than the corresponding positive cells. The hyaluronate binding activity of V5 and V6-positive cells could be restored by pretreatment with anti-CD44 V5 and V6 monoclonal antibodies (MAbs). In addition, transfection of aVV5 and V6-negative cells decreased their hyaluronate binding activity to the levels of CD44 V5 and V6-positive cells. Cells transfected with V5 and V6 recovered their hyaluronate binding activity after pretreatment with MAbs against V5 and V6. These data suggest that cell adhesion involving hyaluronate can be regulated by multiple mechanisms, one of which involves alternative splicing of CD44 isoforms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614382     DOI: 10.1002/(SICI)1096-9896(199803)184:3<291::AID-PATH1>3.0.CO;2-O

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  2 in total

Review 1.  Molecular studies into the role of CD44 variants in metastasis in gastric cancer.

Authors:  H F Hsieh; J C Yu; L I Ho; S C Chiu; H J Harn
Journal:  Mol Pathol       Date:  1999-02

2.  Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function.

Authors:  Jin-Lian Chen; Wei-Xiong Chen; Jin-Shui Zhu; Ni-Wei Chen; Tong Zhou; Ming Yao; Dong-Qing Zhang; Yun-Lin Wu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.